These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

473 related articles for article (PubMed ID: 18261959)

  • 1. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer.
    Naugler WE; Karin M
    Trends Mol Med; 2008 Mar; 14(3):109-19. PubMed ID: 18261959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL-6 as a keystone cytokine in health and disease.
    Hunter CA; Jones SA
    Nat Immunol; 2015 May; 16(5):448-57. PubMed ID: 25898198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From physiology to disease and targeted therapy: interleukin-6 in inflammation and inflammation-associated carcinogenesis.
    Rath T; Billmeier U; Waldner MJ; Atreya R; Neurath MF
    Arch Toxicol; 2015 Apr; 89(4):541-54. PubMed ID: 25632846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-6 trans-signaling and colonic cancer associated with inflammatory bowel disease.
    Rose-John S; Mitsuyama K; Matsumoto S; Thaiss WM; Scheller J
    Curr Pharm Des; 2009; 15(18):2095-103. PubMed ID: 19519447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the IL-6 signaling pathway: a strategy to combat chronic inflammatory diseases and cancer.
    Ataie-Kachoie P; Pourgholami MH; Morris DL
    Cytokine Growth Factor Rev; 2013 Apr; 24(2):163-73. PubMed ID: 23107589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-6 in autoimmune disease and chronic inflammatory proliferative disease.
    Ishihara K; Hirano T
    Cytokine Growth Factor Rev; 2002; 13(4-5):357-68. PubMed ID: 12220549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dangerous liaisons between interleukin-6 cytokine and toll-like receptor families: a potent combination in inflammation and cancer.
    Mansell A; Jenkins BJ
    Cytokine Growth Factor Rev; 2013 Jun; 24(3):249-56. PubMed ID: 23643515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-27: a double agent in the IL-6 family.
    Jones GW; Hill DG; Cardus A; Jones SA
    Clin Exp Immunol; 2018 Jul; 193(1):37-46. PubMed ID: 29437229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-IL-6 treatment for inflammatory bowel diseases: next cytokine, next target.
    Allocca M; Jovani M; Fiorino G; Schreiber S; Danese S
    Curr Drug Targets; 2013 Nov; 14(12):1508-21. PubMed ID: 24102406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inflammatory mediators in gestational diabetes mellitus.
    Richardson AC; Carpenter MW
    Obstet Gynecol Clin North Am; 2007 Jun; 34(2):213-24, viii. PubMed ID: 17572268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-6: A promising cytokine to support liver regeneration and adaptive immunity in liver pathologies.
    Naseem S; Hussain T; Manzoor S
    Cytokine Growth Factor Rev; 2018 Feb; 39():36-45. PubMed ID: 29361380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dissecting Interleukin-6 Classic- and Trans-Signaling in Inflammation and Cancer.
    Garbers C; Rose-John S
    Methods Mol Biol; 2018; 1725():127-140. PubMed ID: 29322414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inflammation: the link between insulin resistance, obesity and diabetes.
    Dandona P; Aljada A; Bandyopadhyay A
    Trends Immunol; 2004 Jan; 25(1):4-7. PubMed ID: 14698276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Obesity, inflammation, and insulin resistance--a mini-review.
    Zeyda M; Stulnig TM
    Gerontology; 2009; 55(4):379-86. PubMed ID: 19365105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Directing transition from innate to acquired immunity: defining a role for IL-6.
    Jones SA
    J Immunol; 2005 Sep; 175(6):3463-8. PubMed ID: 16148087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin 33: an innate alarm for adaptive responses beyond Th2 immunity-emerging roles in obesity, intestinal inflammation, and cancer.
    Schwartz C; O'Grady K; Lavelle EC; Fallon PG
    Eur J Immunol; 2016 May; 46(5):1091-100. PubMed ID: 27000936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers.
    Yao X; Huang J; Zhong H; Shen N; Faggioni R; Fung M; Yao Y
    Pharmacol Ther; 2014 Feb; 141(2):125-39. PubMed ID: 24076269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer.
    Jones SA; Jenkins BJ
    Nat Rev Immunol; 2018 Dec; 18(12):773-789. PubMed ID: 30254251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer.
    Neurath MF; Finotto S
    Cytokine Growth Factor Rev; 2011 Apr; 22(2):83-9. PubMed ID: 21377916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of interleukin-6 signalling in glucose and lipid metabolism.
    Glund S; Krook A
    Acta Physiol (Oxf); 2008 Jan; 192(1):37-48. PubMed ID: 18171428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.